Assets

Collaboration Projects

Biocytogen is dedicated to the development of novel antibody drugs to meet the unmet medical needs, with a particular focus on oncology, autoimmune, inflammatory, metabolic, and other diseases.
The company's assets includes more than 10 assets including monoclonal antibodies, bispecific antibodies, bispecific ADCs, etc. By advancing its R&D capabilities and striving for clinical excellence, Biocytogen aims to deliver transformative therapies to patients in need.
  • 200+
    TAA Projects
  • 20+
    BsADC Projects
  • 30+
    Autoimmune Projects
  • 200+
    Hu-VHH Projects
Request Data Package Schedule a Meeting
related resource
Clinical Candidate Compound Development 0
Clinical Assets
Preclinical Assets
Therapeutic Area Product Name Target (s) Molecular Format Mono/Combo Therapy Indication (s)
Development
Preclinical
IND
Phase I
Phase II
Phase III
 Partner Action
0-0 of 0
20 per page